Results 191 to 200 of about 512,677 (302)

Engineered B7‐H3 Binding in Modular Gp2 Miniproteins

Biotechnology and Bioengineering, EarlyView.
ABSTRACT B7‐H3, an important immune checkpoint modulator of T‐cell function, is a tumor vasculature biomarker and is overexpressed in a variety of cancers. Its expression is associated with tumor growth, metastasis, and poor clinical prognosis, which makes B7‐H3 an appealing target for diagnostics and therapeutics.
Abbigael Harthorn, Hannah K. Windsor, Zachary Schmitz, Nathaniel Cheung, Ebube Agwaramgbo, Benjamin J. Hackel   +5 more
wiley   +1 more source

Theranostic nanoplatform for high‐performance dual‐modal magnetic resonance imaging‐guided therapy of orthotopic hepatocellular carcinoma

BMEMat, EarlyView.
This article introduces a biomimetic Mn‐doped polydopamine nanoplatform (HAMM NPs) coated with cancer cell membranes. It enables targeted hepatocellular carcinoma theranostics via T1/T2 dual‐mode magnetic resonance imaging and tumor microenvironment‐triggered sonodynamic therapy/chemodynamic therapy, achieving potent antitumor efficacy in subcutaneous ...
Jiayin Lin, Wenbo Chen, Xiuqi Hou, Kai Wang, Fan Liu, Ruling Zhang, Zhong Cao, Jian Zheng   +7 more
wiley   +1 more source

Deep Learning Identification of Clear Cell Renal Cell Carcinoma on MR Imaging. [PDF]

J Comput Assist Tomogr
Guo J, Haddad G, Xi Y, Hinojosa L, Hulsey K, Albayrak E, Pedrosa I.   +6 more
europepmc   +1 more source

The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear cell renal cell carcinoma [PDF]

, 2017
et al,, Hsieh, James J
core   +2 more sources

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

The evolution of renal cell carcinoma classification. [PDF]

J Chin Med Assoc
Pan CC.
europepmc   +1 more source

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, EarlyView.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source

Estimate renal cell carcinoma recurrence rates using electronic health records. [PDF]

ESMO Real World Data Digit Oncol
Hou J, Wen J, Bhattacharya R, Wang Z, Morini Sweet S, Xu W, Elfiky A, Wang L, Srivastava R, Lu J, Turzhitsky V, McKay RR, Jayram G, Sundaram M, Cai T, Cai T.   +15 more
europepmc   +1 more source

Unexpected Cervical Lymph Node Metastasis Revealing TFE3‐Rearranged Renal Cell Carcinoma: Intraoperative Cytologic Clues to an Occult Renal Primary

Diagnostic Cytopathology, EarlyView.
ABSTRACT TFE3‐rearranged renal cell carcinoma (TFE3‐rRCC) is a rare subtype of renal carcinoma that may present diagnostic challenges in cytologic specimens, particularly when metastatic disease represents the initial clinical manifestation. We report the case of a 72‐year‐old man presenting with bulky cervical lymphadenopathy clinically suspicious for
Marc P. Pusztaszeri
wiley   +1 more source

Immune Checkpoint Inhibitor-Associated Myocarditis With Multisystem Immune Toxicity in Renal Cell Carcinoma. [PDF]

JACC Case Rep
Chennuri RN, Madine M, Prathipati R, Mannam R, Reddy SR, Davala P, Chilana JK, Bari F.   +7 more
europepmc   +1 more source